Table 1.
Clinical and laboratory data of AAV patients in different AKI stages.
| Stage 1 (n = 43) | Stage 2 (n = 44) | Stage 3 (n = 54) | P-value | |
|---|---|---|---|---|
| Age, Median (IQR) | 59.7(53.4,64.9) | 58.2(42.0,66.9) | 60.3(52.6,69.8) | 0.155 |
| Male, n (%) | 22(51.2) | 21(47.7) | 22(40.7) | 0.573 |
| Smoke, n (%) | 11(25.6) | 14(31.8) | 12(22.2) | 0.842 |
| Hypertension, n (%) | 21(48.8) | 22(50.0) | 24(44.4) | 0.558 |
| Scr at admission, μmol/l, Median (IQR) | 171.0(121.0,270.0) | 224.5(161.0,309.8) | 308.0(232.3,509.5) **## | <0.001 |
| Baseline Scr, μmol/l, Median (IQR) | 116(90,188) | 125(82.5,156.75) | 132.0 (83.3,184.0) | 0.484 |
| Urine red blood cell /ul, Median (IQR) | 188.4(86.8,505.5) | 429.9(93.0,1331.7) | 406.1(80.3,1225.0) | 0.162 |
| White blood cell ×109/L, Median (IQR) | 7.0(5.1,10.2) | 7.7(5.6,10.0) | 8.6(6.5,10.3) | 0.130 |
| Hemoglobin g/L, Median (IQR) | 87.0(77.0,100.0) | 87.0(79.0,99.0) | 80.0(71.0,93.5) | 0.079 |
| Platelet×109/L, Median (IQR) | 265.0(187.0,338.0) | 202.5(158.0,285.5) | 226.0(166.75,289.5) | 0.074 |
| 24h urine protein g, Median (IQR) | 1.56(0.72,3.02) | 1.75(1.13,3.47) | 1.95(0.79,2.75) | 0.434 |
| Albumin g/L, Median (IQR) | 33.9(29.9,37.8) | 34.1(31.3,37.8) | 28.6(25.6,31.1) **## | <0.001 |
| Globulin g/L, Median (IQR) | 29.4(26.3,34.3) | 30.7(24.5,34.3) | 30.0(26.8,32.9) | 0.973 |
| CRP mg/L, Median (IQR) | 14.6 (4.2, 58.9) | 10.5 (3.3, 58.1) | 40.4 (18.8, 85.8) **## | <0.001 |
| MPO-ANCA positive, n (%) | 29(67.4%) | 33(75.0%) | 34(62.9%) | 0.443 |
| MPO, Median (IQR) | 50.0(22.7,78.4) | 66.0(19.4,100.0) | 40.5(12.9,150.0) | 0.928 |
| PR3-ANCA positive, n (%) | 4 (9.3%) | 7 (15.9%) | 5 (9.3%) | 0.516 |
| PR3, Median (IQR) | 1.4(1.1,2.0) | 1.5(1.13,2.68) | 1.4(1.1,2.9) | 0.823 |
| BVAS, Mean ±std. | 16.1±3.8 | 15.3±3.5 | 17.3±3.9# | 0.038 |
| VDI at admission, Median (IQR) | 0 (0,1) | 0 (0, 1) | 0 (0,1) | 0.699 |
| Treatment | ||||
| I.V. Pulse Methylprednisolone | 26(60.5%) | 24(54.3%) | 34(63.0%) | 0.752 |
| Immunosuppressants, n (%) | ||||
| CTX | 19 (48.8%) | 21 (47.7%) | 28 (51.9%) | 0.752 |
| MMF | 21 (48.8%) | 18 (40.9%) | 19 (35.2%) | 0.309 |
Scr, serum creatinine; MPO, myeloperoxidase; BVAS, Birmingham Vasculitis Activity Score; VDI, vascular damage index. **P < 0.01, compared with AKI stage1; #P < 0.05, compared with AKI stage 2; ##P < 0.01, compared with AKI stage 2.
Bolded value: P-value < 0.05.